Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Northwestern University
Beth Israel Deaconess Medical Center
Gilead Sciences
Actuate Therapeutics Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
City of Hope Medical Center
Merck Sharp & Dohme LLC
AstraZeneca
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
AstraZeneca
Pfizer
Merck Sharp & Dohme LLC
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
FBD Biologics Limited
Sun Yat-sen University